Familial Mediterranean Fever.
Age of Onset
Antibodies, Monoclonal
/ therapeutic use
Antibodies, Monoclonal, Humanized
Child
Child, Preschool
Colchicine
/ therapeutic use
Familial Mediterranean Fever
/ diagnosis
Female
Genetic Association Studies
Humans
Immunity, Innate
Inflammation
Interleukin 1 Receptor Antagonist Protein
/ therapeutic use
Interleukin-1
/ antagonists & inhibitors
Male
Pregnancy
Pregnancy Complications
/ genetics
Pyrin
/ deficiency
Journal
Presse medicale (Paris, France : 1983)
ISSN: 2213-0276
Titre abrégé: Presse Med
Pays: France
ID NLM: 8302490
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
15
07
2018
accepted:
15
08
2018
pubmed:
29
1
2019
medline:
26
2
2019
entrez:
29
1
2019
Statut:
ppublish
Résumé
Familial Mediterranean Fever (FMF) is the oldest and the most frequent of all described hereditary periodic fever syndromes. The populations originating from Mediterranean basin carry the highest risk for FMF however it is being increasingly recognized in many parts of the world. It is an autoinflammatory disease with an autosomal recessive transmission. In the majority of the patients it is related with mutations in the MEFV gene that encodes a protein named pyrin. This protein has been shown to act as a regulator of inflammation mediated by IL-1β, which plays a major role in the pathogenesis of FMF. Approximately one-third of the patients have either a single or no mutation which raise questions about its mode of inheritance. FMF is a clinical diagnosis and characterized by self-limited bouts of fever and serositis. The main long-term complication of the disease is AA amyloidosis. The mainstay of treatment is life-long colchicine given daily to prevent the recurrence of febrile attacks and the development of amyloidosis. Patients with insufficient response to colchicine may be treated with anti IL-1 agents.
Identifiants
pubmed: 30686512
pii: S0755-4982(18)30486-X
doi: 10.1016/j.lpm.2018.08.014
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Interleukin 1 Receptor Antagonist Protein
0
Interleukin-1
0
MEFV protein, human
0
Pyrin
0
canakinumab
37CQ2C7X93
Colchicine
SML2Y3J35T
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e61-e76Informations de copyright
Copyright © 2018. Published by Elsevier Masson SAS.